Hercules Capital

Hercules Capital's Life Sciences Team supports transformative companies driving advancements in biotechnology, pharmaceuticals, and?healthcare services. We provide non-dilutive financing to expand clinical development, invest in R&D?and early commercialization, acquire?clinical?assets, and extend cash runway through key value inflection points. With a focus on drug discovery, specialty pharma,?healthcare services,?medical devices, and more, we help life sciences innovators achieve?critical?milestones and unlock their full potential. Connect with us to learn more about the fit and timing of venture lending for your company:?https://lnkd.in/dVjWaV6

Hercules Capital's Technology Team partners with innovative, venture-backed companies to fuel growth and navigate key milestones. From accelerating hiring to expanding into new markets, investing in transformative technologies, and strengthening balance sheets ahead of IPOs or acquisitions, we deliver timely, non-dilutive financing solutions. Our expertise spans enterprise software, cybersecurity,?space, and?defense technologies,?business services,?networking, AI,?media and information services, and more, empowering technology leaders to achieve their boldest ambitions. Connect with us to learn more about the fit and timing of venture lending for your company:?https://lnkd.in/eUWWwN4

Out today -- a NEW episode of Ventured Growth! Episode 34:?The Evolution of Biotech Deals – From Pharma Consolidation to Innovation featuring?Stephen Sands Stephen Sands is a Senior Advisor in?Lazard’s?Global Healthcare Group with a distinguished career in healthcare M&A. With over 35 years of experience, Stephen Sands has guided high-impact transactions that have shaped the biotech and pharma landscape. In this episode,?Janice Bourque?speaks with Stephen about his journey from bioengineer to healthcare M&A leader. They examine the forces that drive today’s major deals, from global expansion to complex valuation challenges, and the strategies that ensure success in a competitive market. Subscribe on Apple, Spotify, Google, and other top podcast directories:?https://lnkd.in/egXdgN3F

Hercules Capital has made a new debt financing commitment to?Alector, Inc.?(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. "We anticipate transformational data from both the AL002 INVOKE-2 Phase 2 trial and the latozinemab INFRONT-3 pivotal Phase 3 trial within our runway," said?Marc Grasso M.D., Chief Financial Officer of Alector. "This credit facility provides additional funding to advance our preclinical pipeline including our proprietary, versatile Alector Brain Carrier blood-brain barrier platform and programs." "Hercules is pleased to enter into a strategic relationship with Alector as it advances its portfolio of assets aimed at treating neurodegenerative diseases," said?Lake McGuire, Managing Director at Hercules Capital. "This capital commitment from Hercules seeks to help Alector deliver new therapeutic options to patients and further advance their novel and proprietary blood-brain barrier technology." Read more:?https://lnkd.in/ewA_8_5c

Hercules Capital has made a secured financing commitment to?Orchestra BioMed?(Nasdaq: OBIO), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. “The Hercules Team is excited to partner with Orchestra BioMed as they progress potential solutions for the treatment of hypertension and atherosclerotic artery disease, two underserved indications that affect tens of millions of people worldwide,” said?Adam Soller, Managing Director at Hercules Capital.?“We are dedicated to backing innovative life sciences companies with creative financings that support them during their development timeline and through regulatory approval.” Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. Learn more:?https://lnkd.in/e4nXWK7J

Hercules Capital has made a new debt financing commitment to?Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. This financing provides funding options to support anticipated key catalysts, including the expected initiation of a confirmatory study of bitopertin in erythropoietic protoporphyria (EPP), a Phase 2 study of DISC-0974 in anemia of myelofibrosis (MF) and a multiple dose study in anemia of non-dialysis dependent chronic kidney disease (NDD-CKD), and a Phase 2 study of DISC-3405 in polycythemia vera (PV). "Hercules is pleased to partner with Disc in the further development of their hematology pipeline,"?said?R. Bryan Jadot, Senior Managing Director and Group Head at Hercules Capital. "We are committed to financing promising life sciences companies to help them achieve their ambitious goals, and we are excited to collaborate with the Disc team ahead of numerous milestones and support them in their next phase of growth." "Not only does this non-dilutive financing strengthen what we believe to be an already strong financial position, it provides optionality and strategic flexibility in future capital formation as we continue to advance our pipeline in pursuit of our mission to deliver innovative treatments to patients suffering from serious hematologic diseases," said?Jean Franchi, Chief Financial Officer of Disc. Read more:?https://lnkd.in/eurMrBem

Hercules is pleased to partner with?Behavox, a leading provider of AI-driven compliance solutions for Financial Services, with a credit facility to support strategic acquisitions and the building of new products to deliver more value to compliance teams globally. "AI continues to become more prevalent in the ecosystem, but only select firms have been able to focus on achieving profitability with a truly differentiated value proposition for their customers," said?Steve Kuo, Senior Managing Director and Technology Group Head at Hercules Capital. "We’re excited to partner with Behavox and support them in their next stage of growth." "We’re excited to partner with Hercules Capital and look forward to advancing our vision of Behavox as the one-stop technology provider for all compliance needs," said?Kiryl Trembovolski, Chief Operating Officer of Behavox. Read the announcement, here:?https://lnkd.in/ewgj4vP3

We are proud to partner with innovators in their field like?Tipalti, a global leader in finance automation, and support their growth and success! It was great to host Tipalti's entire executive team and spend time together at the Warriors game. ??

Hercules Capital, Inc. (NYSE: HTGC) today announced its financial results for the third quarter ended September 30, 2024. "Our ability to continue to diligently scale our investment platform resulted in another quarter of strong financial operating results," stated Scott Bluestein, chief executive officer and chief investment officer of Hercules. "Our results include year-to-date records for total investment income of $371.8 million, an increase of 10%, and net investment income of $244.7 million, an increase of over 12%, year-over year. Both of these metrics were driven by record year-to-date total gross fundings of $1.34 billion, an increase of 3.6% year-over-year. These consistent operating results demonstrate the sustainable strength of our differentiated and diversified investment platform. Hercules continues to benefit from its disciplined growth strategy of maintaining ample liquidity and moderate leverage, as well as the contribution of its private asset management business." Bluestein concluded, "Highlighting our strong performance in the third quarter, we generated net investment income of $0.51 per share, which provided 128% coverage of our base distribution and increased our undistributed earnings spillover to $152.1 million. We declared a supplemental distribution of $0.08 per share in the third quarter, representing our 17th consecutive quarter of issuing a supplemental dividend." ? Read more: https://lnkd.in/eCB35Ux6

Congratulations to Hercules Capital portfolio company?Armis?on closing $200 million in financing to build a multi-generational cybersecurity company, fuel strong organic product innovation and global go-to-market programs, and take advantage of game changing inorganic growth opportunities that may arise.